Provided by Tiger Trade Technology Pte. Ltd.

Verastem

5.33
+0.23504.62%
Volume:170.01K
Turnover:877.04K
Market Cap:467.72M
PE:-1.76
High:5.33
Open:5.02
Low:5.00
Close:5.09
52wk High:11.25
52wk Low:4.01
Shares:87.84M
Float Shares:75.06M
Volume Ratio:0.43
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0223
EPS(LYR):-3.0223
ROE:-1480.15%
ROA:-61.11%
PB:8.18
PE(LYR):-1.76

Loading ...

Press Release: Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Dow Jones
·
Feb 18

Verastem Inc. Schedules Conference Call on Q4 and Full-Year Financial Results

Reuters
·
Feb 18

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM)

TIPRANKS
·
Feb 05

Verastem Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
Feb 04

Verastem reports preliminary Q4 revenue $17.5M, consensus $16.53M

TIPRANKS
·
Feb 04

Verastem Extends Cash Runway and Highlights 2025 Results

TIPRANKS
·
Feb 04

Verastem Inc. erzielt im Gesamtjahr 2025 einen AVMAPKI FAKZYNJA CO-PACK Nettoumsatz von 30,9 Mio. USD

Reuters
·
Feb 04

Verastem Inc. reports FY2025 net product revenue of USD 30.9 million

Reuters
·
Feb 04

Verastem Raises $29.4 Million from Exercise of Outstanding Cash Warrants

Reuters
·
Feb 04

Verastem Inc - Expects to Report a Topline Readout of Primary Endpoint in Ramp 301 Trial in Mid-2027

THOMSON REUTERS
·
Feb 04

Verastem Inc - Expects Cash Runway Into First Half of 2027

THOMSON REUTERS
·
Feb 04

Verastem Inc - Anticipates Lgsoc Commercial Launch and Development Program Will Be Self-Sustaining by Second Half of 2026

THOMSON REUTERS
·
Feb 04

Verastem - Expects Avmapki Fakzynja Co-Pack Net Product Revenues of About $17.5 Mln for Q4 of 2025 and Approximately $30.9 Mln for Full Year 2025

THOMSON REUTERS
·
Feb 04

Verastem - to Engage With FDA in 1H 2026 to Discuss Development Path Forward, Potential Registration-Directed Clinical Trials in Pdac, Nsclc, and Crc

THOMSON REUTERS
·
Feb 04

Press Release: Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Dow Jones
·
Feb 04

Verastem Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $18

THOMSON REUTERS
·
Feb 04

Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM)

TIPRANKS
·
Feb 04

Verastem assumed with a Buy at H.C. Wainwright

TIPRANKS
·
Feb 04

Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up

TIPRANKS
·
Jan 17

Verastem Grants Stock Options and Restricted Stock Units to New Employees

Reuters
·
Jan 13